Cabozantinib

Trade Name: 
Cabometyx
Manufacturer/Distributor: 
Ipsen Biopharmaceuticals Canada Inc.
Classification: 
Antineoplastic agent
ATC Class: 
L01XE26 - caboxantinib
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2018/09/14
Date Marketed in Canada (yyyy/mm/dd): 
2018/09/14
Presentation: 
Tablet: 20 mg. DIN: 02480824
Tablet: 40 mg. DIN: 02480832
Tablet: 60 mg. DIN: 02480840
Comments: 
For the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF)-targeted therapy.
Source: 
Product monograph